MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) CEO Maher Masoud acquired 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 17th. The stock was bought at an average cost of $1.21 per share, with a total value of $121,000.00. Following the completion of the transaction, the chief executive officer directly owned 575,000 shares in the company, valued at $695,750. The trade was a 21.05% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
MaxCyte Stock Performance
MXCT stock traded up $0.08 during trading on Wednesday, reaching $1.25. The company had a trading volume of 969,539 shares, compared to its average volume of 1,085,091. The firm has a 50-day simple moving average of $1.25 and a 200-day simple moving average of $1.07. The company has a market cap of $129.06 million, a price-to-earnings ratio of -4.81 and a beta of 1.49. MaxCyte, Inc. has a twelve month low of $0.64 and a twelve month high of $1.80.
MaxCyte (NASDAQ:MXCT – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. The business had revenue of $8.16 million for the quarter, compared to analyst estimates of $7.39 million. MaxCyte had a negative net margin of 81.40% and a negative return on equity of 15.05%. Sell-side analysts expect that MaxCyte, Inc. will post -0.24 earnings per share for the current year.
Wall Street Analyst Weigh In
Get Our Latest Report on MaxCyte
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in MXCT. Liontrust Investment Partners LLP acquired a new stake in MaxCyte during the third quarter worth about $5,421,000. Marshall Wace LLP grew its position in MaxCyte by 54.0% during the third quarter. Marshall Wace LLP now owns 1,562,275 shares of the company’s stock valued at $1,750,000 after buying an additional 547,497 shares during the period. Empowered Funds LLC acquired a new stake in MaxCyte during the third quarter valued at $66,000. Russell Investments Group Ltd. increased its holdings in MaxCyte by 5,887.4% in the third quarter. Russell Investments Group Ltd. now owns 237,758 shares of the company’s stock valued at $268,000 after buying an additional 233,787 shares in the last quarter. Finally, Susquehanna International Group LLP increased its holdings in MaxCyte by 277.5% in the second quarter. Susquehanna International Group LLP now owns 156,992 shares of the company’s stock valued at $193,000 after buying an additional 115,408 shares in the last quarter. 68.81% of the stock is currently owned by institutional investors and hedge funds.
About MaxCyte
MaxCyte, Inc. develops and commercializes cell-engineering technology used by biotechnology and pharmaceutical companies, academic research institutions, and cell therapy developers. Its platform is designed to introduce molecules such as DNA, RNA, and proteins into cells while maintaining cell viability, supporting applications in cell therapy, gene editing, and drug discovery. The company’s offerings include its Flow Electroporation systems, related consumables, and services. MaxCyte also works with cell therapy developers through licensing agreements that allow them to use its technology in developing and manufacturing therapeutic products.
Further Reading
- Five stocks we like better than MaxCyte
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
